

INTRODUCTION	XV
STUDY GOALS AND OBJECTIVES.....	XV
SCOPE OF STUDY.....	XV
METHODOLOGY AND INFORMATION SOURCES.....	XVI
ANALYST CREDENTIALS.....	XVI
RELATED BCC REPORTS	XVII
BCC ONLINE SERVICES.....	XVII
DISCLAIMER	XVIII
EXECUTIVE SUMMARY	XIX
EXECUTIVE SUMMARY.....	XIX
<i>SUMMARY TABLE MARKET SIZE OF WORLDWIDE BLOOD</i>	
<i>DISORDER TREATMENTS BY REVENUE AT MANUFACTURERS'</i>	
<i>SALES LEVELS, THROUGH 2012 (\$ MILLIONS)</i>	<i>XX</i>
<i>SUMMARY FIGURE MARKET SIZE OF BLOOD DISORDER</i>	
<i>TREATMENTS BY REVENUE AT MANUFACTURERS' SALES</i>	
<i>LEVELS, 2005-2012 (\$ MILLIONS).....</i>	<i>XXI</i>
INDUSTRY OVERVIEW.....	1
STRUCTURE AND FUNCTION OF THE HEMATOLOGICAL	
SYSTEM.....	1
BONE MARROW	1
BLOOD CELLS	1
Red Blood Cells	1
White Blood Cells	2
Platelets	3
SPLEEN.....	3
LYMPH SYSTEM.....	4
LIVER	4
NORMAL CLOTTING MECHANISMS	5
EFFECTS OF AGING ON THE HEMATOLOGIC SYSTEM	6
BLOOD-RELATED MEDICAL CONDITIONS	7
ANEMIA	7
<i>TABLE 1 COMMON CAUSES OF ANEMIA.....</i>	<i>7</i>
Anemia (Continued)	8
Anemia Caused by Decreased Erythrocyte Production	9
Iron Deficiency Anemia	10
Thalassemia	11
Megaloblastic Anemia	11
Vitamin B12 Deficiency.....	11
Anemia of Chronic Disease	12
Aplastic Anemia.....	12
Anemia Caused by Blood Loss	13
Anemia Caused by Increased Erythrocyte Destruction.....	13

Sickle Cell Disease.....	13
Glucose-6-Phosphate Dehydrogenase Deficiency	14
Acquired Hemolytic Anemia	14
Polycythemia.....	15
<i>TABLE 2 TYPES OF ANEMIA.....</i>	<i>16</i>
<i>TABLE 2 (CONTINUED).....</i>	<i>17</i>
HEMOPHILIA.....	18
<i>TABLE 3 COMMON CAUSES OF HEMOPHILIA</i>	<i>18</i>
NEUTROPENIA.....	19
<i>TABLE 4 COMMON INFECTIOUS CAUSES OF NEUTROPENIA.....</i>	<i>19</i>
<i>TABLE 5 COMMON MEDICATION CAUSES OF ANEMIA.....</i>	<i>20</i>
THROMBOCYTOPENIA	20
<i>TABLE 6 COMMON CAUSES OF THROMBOCYTOPENIA</i>	<i>20</i>
THROMBOSIS	21
Thromboembolus	22
Deep Vein Thrombosis.....	22
<i>TABLE 7 COMMON CAUSES OF THROMBOSIS</i>	<i>23</i>
DEMOGRAPHICS AND STATISTICS	23
<i>TABLE 8 U.S. CASES OF SELECTED CHRONIC CONDITIONS/ DISEASES TREATED WITH BLOOD TREATMENTS, ESTIMATED 2007</i>	<i>23</i>
<i>TABLE 8 (CONTINUED).....</i>	<i>24</i>
<i>FIGURE 1 U.S. CASES OF SELECTED LEADING CHRONIC CONDITIONS/DISEASES TREATED WITH BLOOD TREATMENTS, ESTIMATED 2007 (%).....</i>	<i>25</i>
<i>TABLE 9 WORLDWIDE CASES OF SELECTED CHRONIC CONDITIONS/DISEASES TREATED WITH BLOOD TREATMENTS, ESTIMATED 2007.....</i>	<i>26</i>
<i>FIGURE 2 WORLDWIDE CASES OF SELECTED LEADING CHRONIC CONDITIONS/DISEASES TREATED WITH BLOOD TREATMENTS, ESTIMATED 2007 (%).....</i>	<i>27</i>
<i>TABLE 10 U.S. POPULATION BY SELECTED AGE GROUPS AND BY PERCENT OF TOTAL POPULATION, THROUGH 2012 (MILLIONS).....</i>	<i>28</i>
<i>FIGURE 3 U.S. POPULATION BY SELECTED AGE GROUPS, 2005- 2012 (MILLIONS)</i>	<i>28</i>
<i>TABLE 11 WORLDWIDE POPULATION BY SELECTED AGE GROUPS AND BY PERCENT OF TOTAL POPULATION, THROUGH 2012 (MILLIONS)</i>	<i>29</i>
<i>FIGURE 4 WORLDWIDE POPULATION BY SELECTED AGE GROUPS, 2005-2012 (MILLIONS)</i>	<i>29</i>
LICENSING DISPUTES	30
Licensing Disputes (Continued).....	31
Licensing Disputes (Continued).....	32
Licensing Disputes (Continued).....	33

REBATE ISSUES.....	34
FDA RESTRICTIONS ON ANEMIA DRUGS	35
TELEMEDICINE FOR HEMOPHILIA	36
HEMOPHILIA AND JOINT DAMAGE	37
EDUCATION.....	37
COST.....	38
PHARMACEUTICAL LANDSCAPE CHANGES	39
THE IMPACT OF BIOTECHNOLOGY	40
The Impact of Biotechnology (Continued)	41
The Impact of Biotechnology (Continued)	42
<i>TABLE 12 MARKETED BIOTECHNOLOGY BLOOD TREATMENTS.....</i>	<i>43</i>
<i>TABLE 12 (CONTINUED).....</i>	<i>44</i>
<i>TABLE 13 MARKETED BIOTECHNOLOGY PRODUCT IMPACT.....</i>	<i>44</i>
<i>TABLE 13 (CONTINUED).....</i>	<i>45</i>
BIOGENERIC IMPACT.....	46
SEDENTARY LIFESTYLES AND DVT	47
MEDICARE AND THE ELDERLY	47
Medicare and the Elderly (Continued)	48
AIRLINE TRAVEL ISSUES	49
Airline Travel Issues (Continued).....	50
PHARMACEUTICAL REBATE ISSUES.....	51
PRODUCT SEGMENTS BY TYPE	52
ANEMIA TREATMENTS	52
Aranesp/Nespo (Darbepoetin Alfa)	53
Procrit/Eporex (Epoetin Alfa)	53
Epogen (Epoetin Alfa)	53
NeoRecormon/Epogin (Epoetin Beta)	54
<i>TABLE 14 KEY ANEMIA TREATMENTS.....</i>	<i>54</i>
Anabolic Steroids	54
Cyanocobalamin and Combinations	55
Erythropoiesis Stimulants	55
Folic Acid and Derivatives	56
Iron and Derivatives.....	57
HEMOPHILIA TREATMENTS.....	57
Recombinants Group (Baxter).....	58
Kogenate	58
NovoSeven.....	58
<i>TABLE 15 KEY HEMOPHILIA TREATMENTS</i>	<i>59</i>
Antihemophilic Factor	59
Anti-Inhibitor Coagulant Complex	60
Factor IX Complex.....	60
NEUTROPENIA TREATMENTS.....	61
Neulasta/Neupopeg (Pegfilgrastim).....	61
Neupogen/Granulokine (Filgrastim).....	61

<i>TABLE 16 KEY NEUTROPENIA TREATMENTS</i>	62
Granulocyte Colony Stimulating Factor.....	62
Granulocyte Macrophage Colony Stimulating Factor	62
THROMBOSIS TREATMENTS	63
Lovenox (Enoxaparin Sodium).....	63
Plavix (Clopidogrel Bisulfate)	63
<i>TABLE 17 KEY THROMBOSIS TREATMENTS</i>	64
Anticoagulants	64
Antiplatelet Agents.....	65
Antithrombin III Agents	66
Thrombin Inhibitors	67
Thrombolytic Agents	68
NEW APPROVALS	69
<i>TABLE 18 NEWLY APPROVED BLOOD DISORDER TREATMENTS</i>	69
<i>TABLE 18 (CONTINUED)</i>	70
<i>FIGURE 5 PERCENT OF RECENT BLOOD DISORDER APPROVALS</i> <i>BY TREATMENT TYPE (%)</i>	71
MARKET SIZE AND GROWTH	72
<i>TABLE 19 GLOBAL MARKET FOR BLOOD DISORDER</i> <i>TREATMENTS, THROUGH 2012 (\$ MILLIONS)</i>	72
<i>FIGURE 6 GLOBAL MARKET FOR BLOOD DISORDER</i> <i>TREATMENTS, 2005-2012 (\$ MILLIONS)</i>	73
BLOOD DISORDER TREATMENT MARKET BY GEOGRAPHY	74
<i>TABLE 20 GEOGRAPHICAL DISTRIBUTION OF REVENUES IN THE</i> <i>WORLDWIDE BLOOD DISORDER TREATMENTS MARKET,</i> <i>THROUGH 2012 (\$ MILLIONS)</i>	74
<i>FIGURE 7 GEOGRAPHICAL DISTRIBUTION OF REVENUES IN THE</i> <i>WORLDWIDE BLOOD DISORDER TREATMENTS MARKET, 2005-</i> <i>2012 (\$ MILLIONS)</i>	75
BLOOD DISORDER TREATMENT MARKETS BY SEGMENT	75
ANEMIA TREATMENTS MARKET	75
<i>TABLE 21 GLOBAL MARKET FOR ANEMIA TREATMENTS,</i> <i>THROUGH 2012 (\$ MILLIONS)</i>	76
<i>FIGURE 8 GLOBAL MARKET FOR ANEMIA TREATMENTS, 2005-2012</i> <i>(\$ MILLIONS)</i>	76
<i>TABLE 22 GEOGRAPHICAL DISTRIBUTION OF REVENUES IN THE</i> <i>WORLDWIDE ANEMIA TREATMENTS MARKET, THROUGH 2012</i> <i>(\$ MILLIONS)</i>	77
<i>FIGURE 9 GEOGRAPHICAL DISTRIBUTION OF REVENUES IN THE</i> <i>WORLDWIDE ANEMIA TREATMENTS MARKET, 2005-2012</i> <i>(\$ MILLIONS)</i>	77
HEMOPHILIA TREATMENTS MARKET	78
<i>TABLE 23 GLOBAL MARKET FOR HEMOPHILIA TREATMENTS,</i> <i>THROUGH 2012 (\$ MILLIONS)</i>	78

FIGURE 10 GLOBAL MARKET FOR HEMOPHILIA TREATMENTS, 2005-2012 (\$ MILLIONS)	78
TABLE 24 GEOGRAPHICAL DISTRIBUTION OF REVENUES IN THE WORLDWIDE HEMOPHILIA TREATMENTS MARKET, THROUGH 2012 (\$ MILLIONS)	79
FIGURE 11 GEOGRAPHICAL DISTRIBUTION OF REVENUES IN THE WORLDWIDE HEMOPHILIA TREATMENTS MARKET, 2005-2012 (\$ MILLIONS).....	79
NEUTROPENIA TREATMENTS MARKET	80
TABLE 25 GLOBAL MARKET FOR NEUTROPENIA TREATMENTS, THROUGH 2012 (\$ MILLIONS).....	80
FIGURE 12 GLOBAL MARKET FOR NEUTROPENIA TREATMENTS, 2005-2012 (\$ MILLIONS)	81
TABLE 26 GEOGRAPHICAL DISTRIBUTION OF REVENUES IN THE WORLDWIDE NEUTROPENIA TREATMENTS MARKET, THROUGH 2012 (\$ MILLIONS).....	81
FIGURE 13 GEOGRAPHICAL DISTRIBUTION OF REVENUES IN THE WORLDWIDE NEUTROPENIA TREATMENTS MARKET, 2005-2012 (\$ MILLIONS).....	82
THROMBOSIS TREATMENTS	82
TABLE 27 GLOBAL MARKET FOR THROMBOSIS TREATMENTS, THROUGH 2012 (\$ MILLIONS).....	83
FIGURE 14 GLOBAL MARKET FOR THROMBOSIS TREATMENTS, 2005-2012 (\$ MILLIONS)	83
TABLE 28 GEOGRAPHICAL DISTRIBUTION OF REVENUES IN THE WORLDWIDE THROMBOSIS TREATMENTS MARKET, THROUGH 2012 (\$ MILLIONS)	84
FIGURE 15 GEOGRAPHICAL DISTRIBUTION OF REVENUES IN THE WORLDWIDE THROMBOSIS TREATMENTS MARKET, 2005-2012 (\$ MILLIONS).....	84
RESEARCH AND DEVELOPMENT.....	85
TABLE 29 SELECTED BLOOD DISORDER TREATMENTS IN DEVELOPMENT.....	85
TABLE 29 (CONTINUED).....	86
TABLE 29 (CONTINUED).....	87
TABLE 29 (CONTINUED).....	88
TABLE 29 (CONTINUED).....	89
TABLE 29 (CONTINUED).....	90
TABLE 29 (CONTINUED).....	91
TREATMENTS AWAITING APPROVAL/PHASE TRIALS	92
AWAITING APPROVAL.....	92
Angiomax/Angiox.....	92
Hemopure.....	93
Mircera/C.E.R.A./R744	93

EPOCH.....	94
Ferinject	94
Lovenox	94
Plavix	94
Soluble Ferric Pyrophosphate (SFP).....	95
PHASE III CLINICAL TRIALS.....	95
AMG-531	95
Apixaban	95
ATryn	95
AZD-6140	96
Beriplex P/N.....	96
Idraparinux Long-Acting Pentasaccharide	96
Cangrelor	96
Elaprin	96
Ferumoxytol.....	97
Hematide.....	97
Hemospan	97
Hemoxin/Nicosan/Niprisan	97
ICA-17043	98
Mozobil (AMD3100).....	98
NovoSeven.....	98
Oxygent.....	99
PolyHeme	99
Procrit (Epoetin Alfa)	99
Promacta (Eltrombopag Olamine)	100
Refacto AF.....	100
Rendix (Dabigatran Etexilate).....	100
Rivaroxaban (BAY 59-7939).....	100
INDUSTRY STRUCTURE	101
COMPETITIVE ANALYSIS	101
<i>TABLE 30 TOTAL MANUFACTURERS' MARKET SHARES OF BLOOD</i>	
<i>DISORDER TREATMENTS, 2007</i>	102
<i>TABLE 30 (CONTINUED)</i>	103
<i>FIGURE 17 TOTAL MANUFACTURERS' MARKET SHARES OF</i>	
<i>BLOOD DISORDER TREATMENTS, 2007</i>	103
ANEMIA TREATMENTS	104
<i>TABLE 31 TOTAL MANUFACTURERS' MARKET SHARES OF</i>	
<i>ANEMIA TREATMENTS, 2007</i>	104
<i>FIGURE 18 TOTAL MANUFACTURERS' MARKET SHARES OF</i>	
<i>ANEMIA TREATMENTS, 2007 (%)</i>	104
HEMOPHILIA TREATMENTS	105
<i>TABLE 32 TOTAL MANUFACTURERS' MARKET SHARES OF</i>	
<i>HEMOPHILIA TREATMENTS, 2007</i>	105

<i>FIGURE 19 TOTAL MANUFACTURERS' MARKET SHARES OF HEMOPHILIA TREATMENTS, 2007 (%)</i>	105
NEUTROPENIA TREATMENTS.....	106
<i>TABLE 33 TOTAL MANUFACTURERS' MARKET SHARES OF NEUTROPENIA TREATMENTS, 2007</i>	106
<i>FIGURE 20 TOTAL MANUFACTURERS' MARKET SHARES OF NEUTROPENIA TREATMENTS, 2007 (%)</i>	106
THROMBOSIS TREATMENTS	106
<i>TABLE 34 TOTAL MANUFACTURERS' MARKET SHARES OF THROMBOSIS TREATMENTS, 2007</i>	107
<i>FIGURE 21 TOTAL MANUFACTURERS' MARKET SHARES OF THROMBOSIS TREATMENTS, 2007</i>	107
INDUSTRY PARTICIPANTS BY PRODUCT TYPE	108
<i>TABLE 35 BLOOD DISORDER TREATMENT MANUFACTURERS BY PRODUCT TYPE, 2007</i>	108
<i>FIGURE 22 BLOOD DISORDER TREATMENT MARKETS—NUMBER OF KEY MANUFACTURERS BY PRODUCT TYPE, 2007 (%)</i>	109
PATENTS.....	110
PATENT ANALYSIS BY MANUFACTURER.....	110
<i>TABLE 36 SELECTED MANUFACTURER PATENTS FOR BLOOD DISORDER AND RELATED TECHNOLOGY BY APPLICATION, 1976–PRESENT</i>	110
PATENTS BY APPLICATION	111
Anemia Applications	111
Hemophilia.....	111
Neutropenia	111
Thrombosis.....	111
LEADING MARKET MANUFACTURERS	111
<i>TABLE 37 PATENT ANALYSIS BY SELECTED LEADING BLOOD DISORDER TREATMENT MANUFACTURERS, 1976–PRESENT</i>	112
COMPANY PROFILES	113
AMGEN, INC.	113
BAXTER INTL., INC.	113
BAYER AG	114
BIOPURE CORPORATION	115
BRISTOL-MYERS SQUIBB CO.....	116
CHUGAI PHARMACEUTICAL CO., LTD.	116
CSL BEHRING	117
GENZYME	118
TEL: 617/252-7500	118
GLAXOSMITHKLINE, PLC	119
ICAGEN, INC.....	120
MEDICINES COMPANY (THE).....	120

NOVO NORDISK A/S.....	121
ORTHO BIOTECH PRODUCTS, LP	121
ROCHE.....	122
SANOFI-AVENTIS	123
SCHERING-PLOUGH CORP.....	123
WYETH	124
APPENDICES.....	125
COMPANY CONTACT INFORMATION	125
<i>TABLE 38 LIST OF COMPANIES</i>	125
<i>TABLE 38 (CONTINUED)</i>	126
<i>TABLE 38 (CONTINUED)</i>	127
<i>TABLE 38 (CONTINUED)</i>	128
<i>TABLE 38 (CONTINUED)</i>	129
<i>TABLE 38 (CONTINUED)</i>	130
<i>TABLE 38 (CONTINUED)</i>	131
<i>TABLE 38 (CONTINUED)</i>	132
<i>TABLE 38 (CONTINUED)</i>	133
<i>TABLE 38 (CONTINUED)</i>	134
BLOOD DISORDER ASSOCIATIONS AND RESOURCES CONTACT INFORMATION	134
BLOOD DISORDER ASSOCIATIONS (CONTINUED).....	135
BLOOD DISORDER ASSOCIATIONS (CONTINUED).....	136